FR2834991B1 - NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS - Google Patents

NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS

Info

Publication number
FR2834991B1
FR2834991B1 FR0205753A FR0205753A FR2834991B1 FR 2834991 B1 FR2834991 B1 FR 2834991B1 FR 0205753 A FR0205753 A FR 0205753A FR 0205753 A FR0205753 A FR 0205753A FR 2834991 B1 FR2834991 B1 FR 2834991B1
Authority
FR
France
Prior art keywords
igf
antibodies
applications
new anti
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0205753A
Other languages
French (fr)
Other versions
FR2834991A1 (en
Inventor
Liliane Goetsch
Olivier Leger
Nathalie Corvaia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0200653A external-priority patent/FR2834990A1/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0205753A priority Critical patent/FR2834991B1/en
Priority to ES03712270T priority patent/ES2283759T3/en
Priority to CA2473039A priority patent/CA2473039C/en
Priority to EP06126429A priority patent/EP1798242B1/en
Priority to SI200330732T priority patent/SI1461359T1/en
Priority to CNB038024489A priority patent/CN100410275C/en
Priority to EP03712270A priority patent/EP1461359B1/en
Priority to JP2003560053A priority patent/JP4606739B2/en
Priority to EP06126430.5A priority patent/EP1806364B1/en
Priority to DK03712270T priority patent/DK1461359T3/en
Priority to DE60312639T priority patent/DE60312639T2/en
Priority to PCT/FR2003/000178 priority patent/WO2003059951A2/en
Priority to PT03712270T priority patent/PT1461359E/en
Priority to AT03712270T priority patent/ATE357460T1/en
Priority to AU2003216748A priority patent/AU2003216748B2/en
Priority to BRPI0306973A priority patent/BRPI0306973B8/en
Priority to ES06126430T priority patent/ES2427964T3/en
Priority to MXPA04006980A priority patent/MXPA04006980A/en
Publication of FR2834991A1 publication Critical patent/FR2834991A1/en
Priority to US10/735,916 priority patent/US7241444B2/en
Priority to ZA2004/05402A priority patent/ZA200405402B/en
Priority to US11/012,353 priority patent/US7553485B2/en
Application granted granted Critical
Publication of FR2834991B1 publication Critical patent/FR2834991B1/en
Priority to HK05110480A priority patent/HK1078590A1/en
Priority to US11/783,513 priority patent/US7914784B2/en
Priority to US11/783,666 priority patent/US20080063639A1/en
Priority to US11/801,080 priority patent/US20080193445A1/en
Priority to CY20071100801T priority patent/CY1106662T1/en
Priority to US12/388,534 priority patent/US8101180B2/en
Priority to AU2009201674A priority patent/AU2009201674B2/en
Priority to JP2010124341A priority patent/JP2010233575A/en
Priority to US13/037,734 priority patent/US8168410B2/en
Priority to US13/352,599 priority patent/US8808999B2/en
Priority to US13/777,040 priority patent/US20130273031A1/en
Priority to US14/492,636 priority patent/US20150079080A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
FR0205753A 2002-01-18 2002-05-07 NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS Expired - Fee Related FR2834991B1 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
FR0205753A FR2834991B1 (en) 2002-01-18 2002-05-07 NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
EP06126430.5A EP1806364B1 (en) 2002-01-18 2003-01-20 New anti-IGF-IR antibodies and their applications
DE60312639T DE60312639T2 (en) 2002-01-18 2003-01-20 ANTIBODIES TO IGF-IR AND ITS USES
EP06126429A EP1798242B1 (en) 2002-01-18 2003-01-20 Anti-IGF-IR antibodies and their applications
SI200330732T SI1461359T1 (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
CNB038024489A CN100410275C (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
EP03712270A EP1461359B1 (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
JP2003560053A JP4606739B2 (en) 2002-01-18 2003-01-20 Novel anti-IGF-IR antibodies and uses thereof
ES03712270T ES2283759T3 (en) 2002-01-18 2003-01-20 ANTI-IGF-IR ANTIBODIES AND ITS APPLICATIONS.
DK03712270T DK1461359T3 (en) 2002-01-18 2003-01-20 New anti-IGF-IR antibodies and their applications
CA2473039A CA2473039C (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
PCT/FR2003/000178 WO2003059951A2 (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
PT03712270T PT1461359E (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
AT03712270T ATE357460T1 (en) 2002-01-18 2003-01-20 ANTIBODIES TO IGF-IR AND THEIR USES
AU2003216748A AU2003216748B2 (en) 2002-01-18 2003-01-20 Novel anti-IGF-IR antibodies and uses thereof
BRPI0306973A BRPI0306973B8 (en) 2002-01-18 2003-01-20 anti-igf-ir antibodies, their production method and their uses, murine hybridoma, isolated nucleic acid, vector, composition, kit or kit, and in vitro diagnostic method of diseases induced by an overexpression or underexpression of the igf-ir receptor
ES06126430T ES2427964T3 (en) 2002-01-18 2003-01-20 New anti-IGF-IR antibodies and their applications
MXPA04006980A MXPA04006980A (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof.
US10/735,916 US7241444B2 (en) 2002-01-18 2003-12-16 Anti-IGF-IR antibodies and uses thereof
ZA2004/05402A ZA200405402B (en) 2002-01-18 2004-07-07 Novel anti-igf-ir antibodies and uses thereof
US11/012,353 US7553485B2 (en) 2002-01-18 2004-12-16 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
HK05110480A HK1078590A1 (en) 2002-01-18 2005-11-20 Novel anti-igf-ir antibodies and uses thereof
US11/783,513 US7914784B2 (en) 2002-01-18 2007-04-10 Anti-IGF-IR antibodies and uses thereof
US11/783,666 US20080063639A1 (en) 2002-01-18 2007-04-11 Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US11/801,080 US20080193445A1 (en) 2002-01-18 2007-05-08 Novel anti-IGF-IR antibodies and uses thereof
CY20071100801T CY1106662T1 (en) 2002-01-18 2007-06-15 ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
US12/388,534 US8101180B2 (en) 2002-01-18 2009-02-19 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
AU2009201674A AU2009201674B2 (en) 2002-01-18 2009-04-24 Novel anti-IGF-IR antibodies and uses thereof
JP2010124341A JP2010233575A (en) 2002-01-18 2010-05-31 Novel anti-igf-ir antibody and use thereof
US13/037,734 US8168410B2 (en) 2002-01-18 2011-03-01 Anti-IGF-IR antibodies and uses thereof
US13/352,599 US8808999B2 (en) 2002-01-18 2012-01-18 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US13/777,040 US20130273031A1 (en) 2002-01-18 2013-02-26 Novel anti-igf-ir antibodies and uses thereof
US14/492,636 US20150079080A1 (en) 2002-01-18 2014-09-22 Novel anti-igf-ir antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200653A FR2834990A1 (en) 2002-01-18 2002-01-18 New antibodies that bind to human insulin-like growth factor receptor, useful for treatment, prevention and diagnosis of cancers
FR0205753A FR2834991B1 (en) 2002-01-18 2002-05-07 NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS

Publications (2)

Publication Number Publication Date
FR2834991A1 FR2834991A1 (en) 2003-07-25
FR2834991B1 true FR2834991B1 (en) 2004-12-31

Family

ID=27624205

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0205753A Expired - Fee Related FR2834991B1 (en) 2002-01-18 2002-05-07 NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS

Country Status (1)

Country Link
FR (1) FR2834991B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667021B2 (en) 2002-05-24 2010-02-23 Schering Corporation Neutralizing human anti-IGFR antibody

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938428A (en) 2003-11-12 2007-03-28 先灵公司 Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
DE602005025685D1 (en) 2004-12-03 2011-02-10 Schering Corp BIOLOGICAL MARKERS FOR THE PRESELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY
ES2427924T3 (en) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. IGFBP2 biomarker
CA2672828A1 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100480985B1 (en) * 2000-05-19 2005-04-07 이수화학 주식회사 Humanized antibodies to the epidermal growth factor receptor
AU2002231368C1 (en) * 2001-01-05 2018-08-16 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667021B2 (en) 2002-05-24 2010-02-23 Schering Corporation Neutralizing human anti-IGFR antibody

Also Published As

Publication number Publication date
FR2834991A1 (en) 2003-07-25

Similar Documents

Publication Publication Date Title
FR2888850B1 (en) NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
CY2018009I2 (en) IMMUNOSPHERIN VARIATIONS AND THEIR USES
DK2418220T3 (en) INTERFERON-ALPHA ANTIBODIES AND APPLICATIONS THEREOF
MA30684B1 (en) ANTI-MN ANTIBODIES AND METHODS OF USE THEREOF
DK1610820T3 (en) High-concentration antibody and protein formulations
DE602004021904D1 (en) GYRASEINHIBITORS AND THEIR USES
IS2504B (en) Phosphonooxyquinazoline derivatives and their pharmaceutical uses
DK1478648T3 (en) PHOSPHORUS RELATIONS AND APPLICATIONS THEREOF
DE60326611D1 (en) N AND THE EQUAL
ATE420659T1 (en) CRIPTO-BLOCKING ANTIBODIES AND THEIR USE
EE200200626A (en) Anthranilamides and their use as pharmaceuticals
DE60334592D1 (en) Differential pumping device and exposure device
DE50213460D1 (en) SPIROCYCLIC 3-PHENYL-3-SUBSTITUTED-4-KETOLAKTAME AND LACTONS
DK1506291T3 (en) New phospholipases and their applications
FR2834991B1 (en) NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
DE60203475D1 (en) Throttle and throttle
FR2827292B1 (en) MUTE PHOTOPROTEINS AND THEIR APPLICATIONS
NO20024617D0 (en) Aryl and heteroarylsulfonates
FI20031458A (en) Carrying case and carrying structure
FR2834900B1 (en) NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS
FR2857014B1 (en) URANIUM CHELATING PEPTIDES AND THEIR APPLICATIONS
FR2850969B1 (en) ACYLATED AMINOPROPANEDIOLS AND THE LIKE AND THEIR THERAPEUTIC USES
FR2846967B1 (en) NOVEL LIPOPHILIC COMPOUNDS AND USES THEREOF
FI20021792A (en) String and String Structure
DE60219418T8 (en) SILANOLLPHENOL AND NAPHTHOLE

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160129